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 Many case-control investigations have showed the correlation of TP53 gene 
polymorphisms with the risk of breast cancer. However, the findings are not consistent. It has been 
suggested that the investigation of P53 genotype combinations and haplotypes may be more helpful 
than the detection of single polymorphisms. In the present study, we investigated the association of 
P53 intron 3 and codon 72 polymorphisms, as well as their Haplotypes and genotype combinations, 
with the development of breast cancer among Azeri women of Iran. 
 A total of 143 Iranian-Azeri females suffering from breast cancer and 160 ethnically and 
age-matched healthy females participated in this study. Intron 3 genotype was indicated by length 
analysis of PCR amplicon on polyacrylamide gels and allele specific–polymerase chain reaction 
(AS-PCR) was applied for genotyping Arg72Pro variation. Data analysis was performed using the 
JavaStat online statistics package and SHEsis online program. 
 Our findings did not show a significant association of P53 intron 3 and codon 72 
polymorphisms with the risk of breast neoplastic tumors among Iranian-Azeri women. However, the 
(-16ins/+16ins) (Arg/Arg) combined genotype and (+16Ins-Arg) haplotype had a higher frequency 
in patients in comparison with the control group (OR=3.816; 95%CI: 0.906-18.459; P=0.047 and 
OR=3.941; 95%CI: 1.583-9.812; P=0.002, respectively). 
 In our study, (-16ins/+16ins) (Arg/Arg) genotype combination and (+16ins-Arg) 
haplotype showed significant correlation with the increased susceptibility to breast cancer 
development in Iranian-Azeri females. 
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Table 1. Primers applied for genotyping of codon 72 and intron 3 SNPs 
Primer name Primer sequence PCR product (bp) 
Annealing 
Temperature (°C) 
ArgF 
ArgR 
5′-TCCCCCTTGCCGTCCCAA-3′ 
5′-CTGGTGCAGGGGCCACGC-3′ 
144 61 
ProF 
ProR 
5′-GCCAGAGGCTGCTCCCCC-3′ 
5′-CGTGCAAGTCACAGACTT-3′ 
177 62 
BetaF 
BetaR 
5′-CAATGTATCATGCCTCTTTGCACC-3′ 
5′-GAGTCAAGGCTGAGAGATGCAGGA-3′ 
861 60 
Int3F 
Int3R 
5′-TGGGACTGACTTTCTGCTCTT-3′ 
5′-TCAAATCATCCATTGCTTGG-3′ 
179 or 195 61 
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Table 2. Clinicopathological characteristics of patients involved in 
this study 
Parameters n (%) 
Age (years)  
≤47 77 (53.8%) 
>47 66 (46.2%) 
Tumor type  
DCIS 6 (4.2%) 
IDC 133 (93%) 
ILC 4 (2.8%) 
Grade  
I 14 (9.8%) 
II 119 (83.2%) 
III 10 (7%) 
Tumor size  
≤3.5 79 (55.2%) 
>3.5 64 (44.8%) 
Lymph node metastases  
Positive 91 (63.6%) 
Negative 52 (39.4%) 
Tumor stage  
Stage 0 6 (4.2%) 
Early (I & II) 61 (42.7%) 
Late (III & IV) 76 (53.1%) 
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Table 3. Genotypes and allelic frequencies of P53 gene SNPs in patient and control groups 
polymorphisms cases controls Odds ratio (95 % CI) P value 
Intron 3 16 bp insertion 
−16ins/−16in 88 (61.5%) 104 (65.0%) 0.862 (0.525-1.414) 0.532 
−16ins/+16in 45 (31.5%) 45 (28.1%) 1.173(0.696-1.980) 0.525 
+16ins/+16in 10 (7.0%) 11 (6.9%) 1.018 (0.386-2.678) 0.968 
(−16ins/+16ins) + (+16ins/+16ins) 55 (38.5%) 56 (35.0%) 1.161 (0.707-1.905) 0.532 
−16ins 221 (77.3%) 253 (79.1%) 0.900 (0.601-1.349) 0.594 
+16in 65 (22.7%) 67 (20.9%) 1.111 (0.741-1.664) 0.594 
Codon 72 Arg/Pro 
Arg/Arg 63 (44.0%) 54 (33.8%) 1.546 (0.945-2.530) 0.066 
Arg/Pro 54 (37.8%) 74 (46.3%) 0.705 (0.434-1.146) 0.135 
Pro/Po 26 (18.2%) 32 (20.0%) 0.889 (0.481-1.641) 0.688 
(Arg/Pro) + (Pro/Po) 80 (56.0%) 106 (66.3%) 0.562 (0.344-0.917) 0.014* 
Arg 180 (64.7%) 182 (56.9%) 1.288 (0.917-1.809) 0.129 
Pro 106 (35.3%) 138 (43.1%) 0.777 (0.553-1.091) 0.129 
*P<0.05 
Table 4. The frequency distribution of P53 genotype combinations in patients and control groups 
Intron 3 Exon 4 Cases (n=143) Controls (n=160) OR (95%CI) P value 
−16/−16 Arg/Arg 49 (34.3 %) 51 (31.9 %) reference - 
−16/−16 Arg/Pro 30 (20.1 %) 44 (27.5 %) 0.710 (0.369-1.362) 0.285 
−16/−16 Pro/Pro 11 (7.7 %) 9 (5.6 %) 1.154 (0.401-3.342) 0.770 
−16/+16 Arg/Arg 11 (7.7 %) 3 (1.9 %) 3.816 (0.906-18.459) 0.047 
−16/+16 Arg/Pro 26 (18.2 %) 28 (17.5 %) 0.966 (0.472-1.977) 1.000 
−16/+16 Pro/Pro 8 (5.6 %) 14 (8.7 %) 0.540 (0.188-1.522) 0.199 
+16/+16 Arg/Arg 2 (1.4 %) 0 Inf a (0.221-Inf) 0.496* 
+16/+16 Arg/Pro 0 2 (1.2 %) 0.000 (0.000-4.028) 0.243 
+16/+16 Pro/Pro 6 (4.2 %) 9 (5.6 %) 0.630 (0.183-2.118) 0.582 
*P<0.05 
aInf: Infinity 
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Table 5. The frequency distribution of P53 gene haplotypes in case and control groups 
Pairwise haplotypes cases controls OR (95%CI) P value 
(−16ins -Arg) 0.557 0.549 1.032 (0.749-1.422) 0.849 
(−16ins -Pro) 0.216 0.241 0.865 (0.591-1.265) 0.454 
(+16ins -Arg) 0.072 0.019 3.941 (1.583-9.812) 0.002* 
(+16ins -Pro) 0.155 0.190 0.782 (0.511-1.196) 0.256 
*P<0.05 
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